Stefan Kaluz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5398131/publications.pdf

Version: 2024-02-01

236925 223800 2,135 52 25 46 h-index citations g-index papers 53 53 53 3411 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Targeting HIF-activated collagen prolyl 4-hydroxylase expression disrupts collagen deposition and blocks primary and metastatic uveal melanoma growth. Oncogene, 2021, 40, 5182-5191.	5.9	13
2	EZH2 targeting reduces medulloblastoma growth through epigenetic reactivation of the BAI1/p53 tumor suppressor pathway. Oncogene, 2020, 39, 1041-1048.	5.9	33
3	Arylsulfonamide 64B Inhibits Hypoxia/HIF-Induced Expression of c-Met and CXCR4 and Reduces Primary Tumor Growth and Metastasis of Uveal Melanoma. Clinical Cancer Research, 2019, 25, 2206-2218.	7.0	45
4	Taking a HIF pill for old age diseases?. Aging, 2018, 10, 290-292.	3.1	5
5	Design and synthesis of benzopyran-based inhibitors of the hypoxia-inducible factor-1 pathway with improved water solubility. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 992-1001.	5. 2	7
6	Purifying Properly Folded Cysteine-rich, Zinc Finger Containing Recombinant Proteins for Structural Drug Targeting Studies: the CH1 Domain of p300 as a Case Example. Bio-protocol, 2017, 7, .	0.4	2
7	A novel small-molecule arylsulfonamide causes energetic stress and suppresses breast and lung tumor growth and metastasis. Oncotarget, 2017, 8, 99245-99260.	1.8	8
8	A role for activated Cdc42 in glioblastoma multiforme invasion. Oncotarget, 2016, 7, 56958-56975.	1.8	32
9	Tyr Phosphorylation of PDP1 Toggles Recruitment between ACAT1 and SIRT3 to Regulate the Pyruvate Dehydrogenase Complex. Molecular Cell, 2014, 53, 534-548.	9.7	247
10	Hypoxia inducible factor pathway inhibitors as anticancer therapeutics. Future Medicinal Chemistry, 2013, 5, 553-572.	2.3	116
11	A proprotein convertase/MMP-14 proteolytic cascade releases a novel 40 kDa vasculostatin from tumor suppressor BAI1. Oncogene, 2012, 31, 5144-5152.	5.9	71
12	5-D confocal imaging to visualize glioblastoma spheroid invasion into the extracellular matrix. Microscopy and Microanalysis, 2012, 18, 180-181.	0.4	0
13	Arylsulfonamide KCN1 Inhibits <i>In Vivo</i> Glioma Growth and Interferes with HIF Signaling by Disrupting HIF-1α Interaction with Cofactors p300/CBP. Clinical Cancer Research, 2012, 18, 6623-6633.	7.0	74
14	Binding Model for the Interaction of Anticancer Arylsulfonamides with the p300 Transcription Cofactor. ACS Medicinal Chemistry Letters, 2012, 3, 620-625.	2.8	15
15	Design and Synthesis of Novel Small-Molecule Inhibitors of the Hypoxia Inducible Factor Pathway. Journal of Medicinal Chemistry, 2011, 54, 8471-8489.	6.4	44
16	Sulfonamides as a new scaffold for hypoxia inducible factor pathway inhibitors. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 5528-5532.	2.2	32
17	At the crossroads of cancer and inflammation: Ras rewires an HIF-driven IL-1 autocrine loop. Journal of Molecular Medicine, 2011, 89, 91-94.	3.9	17
18	Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase 1act/Tubulin Interaction Is an Important Determinant of Mitotic Stability in Cultured HT1080 Human Fibrosarcoma Cells. Cancer Research, 2010, 70, 6004-6014.	0.9	17

#	Article	IF	Citations
19	Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: A one transcription factor (HIF-1) show?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2009, 1795, 162-172.	7.4	161
20	PI3K/Akt activity has variable cell-specific effects on expression of HIF target genes, CA9 and VEGF, in human cancer cell lines. Cancer Letters, 2009, 282, 109-115.	7.2	53
21	Does inhibition of degradation of hypoxiaâ€inducible factor (HIF) α always lead to activation of HIF? lessons learnt from the effect of proteasomal inhibition on HIF activity. Journal of Cellular Biochemistry, 2008, 104, 536-544.	2.6	25
22	Rational design of minimal hypoxia-inducible enhancers. Biochemical and Biophysical Research Communications, 2008, 370, 613-618.	2.1	27
23	Regulation of gene expression by hypoxia: Integration of the HIF-transduced hypoxic signal at the hypoxia-responsive element. Clinica Chimica Acta, 2008, 395, 6-13.	1.1	131
24	Comment on the role of FIH in the inhibitory effect of bortezomib on hypoxia-inducible factor-1. Blood, 2008, 111, 5258-5259.	1.4	5
25	The role of extracellular signal-regulated protein kinase in transcriptional regulation of the hypoxia marker carbonic anhydrase IX. Journal of Cellular Biochemistry, 2006, 97, 207-216.	2.6	25
26	Proteasomal Inhibition Attenuates Transcriptional Activity of Hypoxia-Inducible Factor 1 (HIF-1) via Specific Effect on the HIF-1Î \pm C-Terminal Activation Domain. Molecular and Cellular Biology, 2006, 26, 5895-5907.	2.3	109
27	High cell density induces expression from the carbonic anhydrase 9 promoter. BioTechniques, 2004, 36, 228-234.	1.8	4
28	DNA Damage Is a Prerequisite for p53-Mediated Proteasomal Degradation of HIF- $1\hat{l}\pm$ in Hypoxic Cells and Downregulation of the Hypoxia Marker Carbonic Anhydrase IX. Molecular and Cellular Biology, 2004, 24, 5757-5766.	2.3	84
29	Biodistribution and pharmacokinetics of 1251-labeled monoclonal antibody M75 specific for carbonic anhydrase IX, an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinoma. International Journal of Cancer, 2003, 105, 873-881.	5.1	89
30	Genetic Interaction between Distinct Dobrava Hantavirus Subtypes in <i>Apodemus agrarius</i> and <i>A. flavicollis</i> in Nature. Journal of Virology, 2003, 77, 804-809.	3.4	74
31	Expression of the hypoxia marker carbonic anhydrase IX is critically dependent on SP1 activity. Identification of a novel type of hypoxia-responsive enhancer. Cancer Research, 2003, 63, 917-22.	0.9	57
32	Lowered oxygen tension induces expression of the hypoxia marker MN/carbonic anhydrase IX in the absence of hypoxia-inducible factor 1 alpha stabilization: a role for phosphatidylinositol 3'-kinase. Cancer Research, 2002, 62, 4469-77.	0.9	118
33	Characterization of the MN/CA 9 promoter proximal region: a role for specificity protein (SP) and activator protein 1 (AP1) factors. Biochemical Journal, 2001, 359, 669.	3.7	25
34	Characterization of the MN/CA 9 promoter proximal region: a role for specificity protein (SP) and activator protein 1 (AP1) factors. Biochemical Journal, 2001, 359, 669-677.	3.7	34
35	Block-replacement mutagenesis for functional dissection of multiple transcription factor complexes. New Biotechnology, 2001, 18, 9-11.	2.7	0
36	P53 tumour suppressor modulates transcription of the TATA-less gene coding for the tumour-associated carbonic anhydrase MN/CA IX in MaTu cells. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2000, 1491, 20-26.	2.4	15

#	Article	IF	Citations
37	Acute Effects of Interferon on Estrogen Receptor Function Do Not Involve the Extracellular Signal-Regulated Kinases p42mapkand p44mapk. Journal of Interferon and Cytokine Research, 2000, 20, 225-234.	1.2	0
38	Inverse PCR-Generated Internally Deleted Constructs for Direct Characterization of Promoter Regulatory Regions. BioTechniques, 1999, 26, 446-450.	1.8	8
39	Transcriptional Regulation of the MN/CA 9 Gene Coding for the Tumor-associated Carbonic Anhydrase IX. Journal of Biological Chemistry, 1999, 274, 32588-32595.	3.4	42
40	Identification of MaTu-MX Agent as a New Strain of Lymphocytic Choriomeningitis Virus (LCMV) and Serological Indication of Horizontal Spread of LCMV in Human Population. Virology, 1999, 257, 73-83.	2.4	24
41	Modified gel electrophoresis loading buffer indicating addition of DNA samples. Technical Tips Online, 1998, 3, 108.	0.2	0
42	Sequence variability in the A/B region of the estrogen receptor. Animal Biotechnology, 1997, 8, 221-226.	1.5	3
43	Sequencing analysis of prion genes from red deer and camel. Gene, 1997, 199, 283-286.	2.2	20
44	Heterogeneity in the third intracytoplasmic region of the oxytocin receptor-encoding gene. Gene, 1996, 172, 313-314.	2.2	4
45	Rapid PCR-mediated bidirectional deletions. Trends in Genetics, 1996, 12, 453-454.	6.7	3
46	Application of suppression PCR to the megaprimer method for site-directed mutagenesis. Genetic Analysis, Techniques and Applications, 1996, 13, 165-169.	1.5	12
47	Structure of an ovine interferon receptor and its expression in endometrium. Journal of Molecular Endocrinology, 1996, 17, 207-215.	2.5	15
48	Ligation-independent cloning of PCR products with primers containing nonbase residues. Nucleic Acids Research, 1994, 22, 4845-4845.	14.5	12
49	Assignment of the Human Pulmonary Surfactant Protein D Gene (SFTP4) to 10q22-q23 Close to the Surfactant Protein A Gene Cluster. Genomics, 1993, 17, 294-298.	2.9	60
50	Directional cloning of PCR products using exonuclease III. Nucleic Acids Research, 1992, 20, 4369-4370.	14.5	36
51	Molecular cloning of the cDNA coding for properdin, a positive regulator of the alternative pathway of human complement. European Journal of Immunology, 1991, 21, 771-776.	2.9	60
52	A novel rapid method for detection of PCR products. Nucleic Acids Research, 1991, 19, 4012-4012.	14.5	3